Sage Therapeutics, Inc. Stock price

Equities

SAGE

US78667J1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
19.04 USD +2.26% Intraday chart for Sage Therapeutics, Inc. -3.25% -12.14%
Sales 2024 * 34.65M Sales 2025 * 127M Capitalization 1.14B
Net income 2024 * -384M Net income 2025 * -312M EV / Sales 2024 * 18.9 x
Net cash position 2024 * 491M Net cash position 2025 * 372M EV / Sales 2025 * 6.1 x
P/E ratio 2024 *
-3.04 x
P/E ratio 2025 *
-3.92 x
Employees 487
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.44%
More Fundamentals * Assessed data
Dynamic Chart
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating MT
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines MT
Transcript : Sage Therapeutics, Inc., Q4 2023 Earnings Call, Feb 14, 2024
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M MT
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Wedbush Adjusts Sage Therapeutics' Price Target to $24 From $22, Keeps Neutral Rating MT
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC CI
Oppenheimer Adjusts Sage Therapeutics Price Target to $23 From $20, Maintains Perform Rating MT
Transcript : Sage Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM
Sage Therapeutics, Inc. Announces Changes to Board of Directors CI
More news
1 day+2.26%
1 week-3.25%
Current month-11.36%
1 month-16.16%
3 months-14.47%
6 months-10.65%
Current year-12.14%
More quotes
1 week
18.42
Extreme 18.42
20.32
1 month
18.42
Extreme 18.42
23.00
Current year
18.42
Extreme 18.42
28.26
1 year
16.52
Extreme 16.515
59.99
3 years
16.52
Extreme 16.515
81.00
5 years
16.52
Extreme 16.515
193.56
10 years
16.52
Extreme 16.515
195.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-09-30
Founder 73 10-04-15
Director of Finance/CFO 61 13-02-28
Members of the board TitleAgeSince
Director/Board Member 71 13-08-13
Founder 73 10-04-15
Chief Executive Officer 60 20-09-30
More insiders
Date Price Change Volume
24-03-27 19.04 +2.26% 551,465
24-03-26 18.62 -0.37% 830,173
24-03-25 18.69 -2.76% 530,933
24-03-22 19.22 -3.76% 447,310
24-03-21 19.97 +1.47% 791,236

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing brain health medicines. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous systems (CNS) receptor systems, GABA and NMDA. It targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The Company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
19.04 USD
Average target price
27.42 USD
Spread / Average Target
+44.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Sage Therapeutics, Inc. - Nasdaq